These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 19597986

  • 1. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, Xue S, Bernstein JL.
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [Abstract] [Full Text] [Related]

  • 2. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group.
    Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton-Culver H, Stovall M, Bertelsen L, Haile RW, Bernstein JL, WECARE Study Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1411-8. PubMed ID: 18250348
    [Abstract] [Full Text] [Related]

  • 3. Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
    Figueiredo JC, Brooks JD, Conti DV, Poynter JN, Teraoka SN, Malone KE, Bernstein L, Lee WD, Duggan DJ, Siniard A, Concannon P, Capanu M, Lynch CF, Olsen JH, Haile RW, Bernstein JL.
    Breast Cancer Res Treat; 2011 Jun 20; 127(3):819-29. PubMed ID: 21161372
    [Abstract] [Full Text] [Related]

  • 4. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW, WECARE Study Collaborative Group.
    Eur J Cancer; 2013 Sep 20; 49(14):2979-85. PubMed ID: 23706288
    [Abstract] [Full Text] [Related]

  • 5. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Su L, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    Int J Cancer; 2020 Jun 15; 146(12):3335-3342. PubMed ID: 32037537
    [Abstract] [Full Text] [Related]

  • 6. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.
    J Natl Cancer Inst; 2002 Dec 04; 94(23):1773-9. PubMed ID: 12464649
    [Abstract] [Full Text] [Related]

  • 7. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
    Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC, Haile RW, Thomas DC, Begg CB, Bernstein JL.
    J Clin Oncol; 2013 Feb 01; 31(4):433-9. PubMed ID: 23269995
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE, WECARE Collaborative Study Group.
    Breast Cancer Res Treat; 2010 Sep 01; 123(2):491-8. PubMed ID: 20135344
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL, WECARE Study Collaborative Group.
    Breast Cancer Res; 2017 Jul 19; 19(1):83. PubMed ID: 28724391
    [Abstract] [Full Text] [Related]

  • 11. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
    Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC, Giles GG, McCredie MR, Hopper JL, Whittemore AS.
    Cancer Epidemiol Biomarkers Prev; 2005 Feb 19; 14(2):350-6. PubMed ID: 15734957
    [Abstract] [Full Text] [Related]

  • 12. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, Noguès C, Lasset C, Berthet P, Meijers-Heijboer H, Gerdes AM, Olsson H, Caldes T, van Leeuwen FE, Rookus MA.
    J Clin Oncol; 2007 Sep 01; 25(25):3831-6. PubMed ID: 17635951
    [Abstract] [Full Text] [Related]

  • 13. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
    Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, Wappenschmidt B, Hübbel V, Maringa M, Reichstein-Gnielinski S, Hahnen E, Bartram CR, Dikow N, Schott S, Speiser D, Horn D, Fallenberg EM, Kiechle M, Quante AS, Vesper AS, Fehm T, Mundhenke C, Arnold N, Leinert E, Just W, Siebers-Renelt U, Weigel S, Gehrig A, Wöckel A, Schlegelberger B, Pertschy S, Kast K, Wimberger P, Briest S, Loeffler M, Bick U, Schmutzler RK, German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    Int J Cancer; 2020 Feb 15; 146(4):999-1009. PubMed ID: 31081934
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, Ursin G.
    Cancer Epidemiol Biomarkers Prev; 2008 Nov 15; 17(11):3170-8. PubMed ID: 18990759
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L, WECARE Study Collaborative Group, Bernstein JL.
    J Clin Oncol; 2018 May 20; 36(15):1513-1520. PubMed ID: 29620998
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.